Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

Yao, Liqin; Jia, Gang; Lu, Lingeng; Ma, Wenxue

Yao, Liqin; Jia, Gang; Lu, Lingeng; Ma, Wenxue.

Afiliação

Yao L; Department of Breast and Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Huzhou University, Huzhou 313000, China.
Jia G; Department of Medical Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
Lu L; Department of Chronic Disease Epidemiology, School of Medicine, Yale School of Public Health, New Haven, CT 06520, USA.
Ma W; Yale Cancer Center, Yale University, 60 College Street, New Haven, CT 06520, USA.

Curr Oncol ; 29(7): 4902-4913, 2022 07 12.

Article em En | MEDLINE | ID: mdl-35877249

Assuntos

Neoplasias da Mama; Terapia Neoadjuvante; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Neoplasias da Mama/patologia; Feminino; Humanos; Linfócitos do Interstício Tumoral/metabolismo; Linfócitos do Interstício Tumoral/patologia

Palavras-chave

Human Leukocyte Antigen-DR (HLA-DR); breast cancer; cytotoxic T lymphocytes (CTLs); neoadjuvant chemotherapy (NACT); pathologic complete response (pCR); tumor-infiltrating lymphocytes (TILs)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia Neoadjuvante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Curr Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google